Home/Filings/4/0001209191-18-005831
4//SEC Filing

Remeditex Ventures LLC 4

Accession 0001209191-18-005831

CIK 0001566044other

Filed

Jan 28, 7:00 PM ET

Accepted

Jan 29, 4:19 PM ET

Size

16.3 KB

Accession

0001209191-18-005831

Insider Transaction Report

Form 4
Period: 2018-01-25
Transactions
  • Conversion

    Common Stock

    2018-01-29+2,6501,585,504 total
  • Purchase

    Common Stock

    2018-01-25$17.00/sh+100,000$1,700,0001,582,854 total
  • Conversion

    Common Stock

    2018-01-29+304,5762,761,663 total
  • Conversion

    Series B Preferred Stock

    2018-01-292,351,0970 total
    Common Stock (871,583 underlying)
  • Conversion

    Series A Preferred Stock

    2018-01-297,1500 total
    Common Stock (2,650 underlying)
  • Conversion

    Series C Preferred Stock

    2018-01-29821,5960 total
    Common Stock (304,576 underlying)
  • Conversion

    Common Stock

    2018-01-29+871,5832,457,087 total
Footnotes (1)
  • [F1]Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

Issuer

Menlo Therapeutics, Inc.

CIK 0001566044

Entity typeother
IncorporatedTX

Related Parties

1
  • filerCIK 0001627363

Filing Metadata

Form type
4
Filed
Jan 28, 7:00 PM ET
Accepted
Jan 29, 4:19 PM ET
Size
16.3 KB